CLINICAL_TRIALS
ClinicalTrials.gov record update
The Use of Alpha-linolenic (ALA), Docosahexaenoic (DHA) and Eicosapanthene (EPA) Esters in the Prevention of Cardiovascular Diseases in Adults.
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT04743050
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:37:49.551046+00:00
- Published At
- 2021-02-08T00:00:00+00:00
- Record Updated At
- 2021-02-08
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Fatty Acids", "Alpha-Linolenic Acid", "Docosahexaenoic Acids", "Eicosapentaenoic Acid", "Preventive Health Services", "Preventive Medicine", "Cardiovascular Diseases", "Anti-Inflammatory Agents"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2021-02-08"- protocolSection.identificationModule.nctId
"NCT04743050"- protocolSection.identificationModule.officialTitle
"The Use of Alpha-linolenic (ALA), Docosahexaenoic (DHA) and Eicosapanthene (EPA) Esters in the Prevention of Cardiovascular Diseases in Adults."- protocolSection.statusModule.overallStatus
"UNKNOWN"- protocolSection.designModule.phases
["PHASE3"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.